Samjin Pharmaceutical Co., Ltd. (005500)
Market Closed
12 Jun, 06:30
KRX SM KRX SM Primary ₩
19,310. 00
+420
+2.2234%
₩
250.06B Market Cap
- P/E Ratio
3,200% Div Yield
95,941 Volume
- Eps
₩ 18,890
Previous Close Want to track 005500 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
005500 closed Friday higher at ₩19,310, an increase of 2.2234% from Thursday's close, completing a monthly decrease of -3.4017% or -₩680. Over the past 12 months, 005500 stock lost -2.9648%.
005500 pays dividends to its shareholders, with the most recent payment made on Apr 14, 2026. The next estimated payment will be in In 9 months on Apr 14, 2027 for a total of ₩800.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 185.9144%, based on the last three reports.
Samjin Pharmaceutical Co., Ltd. has completed 6 stock splits, with the recent split occurring on Dec 29, 2010.
The company's stock is traded on one exchange.
Samjin Pharmaceutical Co., Ltd. (005500) FAQ
What is the stock price today?
The current price is ₩19,310.00.
On which exchange is it traded?
Samjin Pharmaceutical Co., Ltd. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 005500.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 3,200%.
What is its market cap?
As of today, the market cap is 250.06B.
Has Samjin Pharmaceutical Co., Ltd. ever had a stock split?
Samjin Pharmaceutical Co., Ltd. had 6 splits and the recent split was on Dec 29, 2010.
Samjin Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Kyu Seok Cho CEO | KRX SM Exchange | KR7005500004 ISIN |
| South Korea Country | 586 Employees | 29 Dec 2025 Last Dividend | 29 Dec 2010 Last Split | - IPO Date |
Overview
Samjin Pharmaceuticals Co., Ltd., founded in 1968 and based in Seoul, South Korea, is a prominent player in the pharmaceutical industry, focusing on the manufacturing and selling of medicines. The company is dedicated to providing a wide range of pharmaceutical products, including over-the-counter medicines, prescription drugs, and therapies undergoing clinical trials. Its state-of-the-art research and development division is working tirelessly on innovating treatments for various chronic and critical diseases, showcasing its commitment to enhancing healthcare outcomes globally.
Products and Services
Samjin Pharmaceuticals Co., Ltd. offers an extensive portfolio of pharmaceutical products, targeting a wide spectrum of health conditions:
- Gevorin: An over-the-counter anti-inflammatory painkiller used to alleviate pain and inflammation.
- Trestan: An appetite stimulant designed to help individuals gain healthy weight.
- Flaris: An anti-thrombotic agent used to prevent blood clots, thereby reducing the risk of strokes and heart attacks.
- Nutilin: A medication aimed at improving brain function, specifically developed for enhancing cognitive abilities.
- SA001: Currently in Phase II clinical trials, SA001 is being tested for its efficacy in treating dry eye syndrome and Sjogren's syndrome.
- SJP1804: A medication in Phase I clinical trials designed for the treatment of macular degeneration, a leading cause of vision loss.
- SJP1604: This Phase I clinical trial drug is being developed for the treatment of cancer, showcasing the company’s efforts in oncology.
- SJP1901 and SJP1902: Both are candidates for cancer treatment, signifying Samjin Pharmaceuticals' commitment to advancing cancer therapy alternatives.
- SJP 1801: Aimed at treating Alzheimer's and Parkinson's disease, SJP 1801 is part of the company's neurological disorder research initiative.
- SJP006: An anti-viral product designed to combat various viral infections, highlighting the company's role in infectious disease control.
- SJP003: A treatment option for diabetes, SJP003 represents the company’s investment in addressing this widespread, chronic condition.
- SJP1602: Currently in preclinical development, SJP1602 is another cancer treatment therapy, underlining the company's strong focus on oncology.
Contact Information
Address: 121 Wausan Ro
Phone: 82 2 3140 0700
Website: https://www.samjinpharm.co.kr
